Search
for

    Sort by

    Community Join

    690-720 / 1000+ results
      Hair Growth or Loss Tracking Tool

      community Hair Growth or Loss Tracking Tool

      in Research  141 upvotes 1 year ago
      A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

      community (Serious) Updates and discussion, new treatments in development

      in Treatment  7 upvotes 2 years ago
      Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

      community Pyrilutamide for non-5AR users?

      in Treatment  10 upvotes 1 year ago
      Pyrilutamide is considered by some as an alternative for those avoiding 5AR inhibitors like finasteride and dutasteride, but opinions on its effectiveness vary. Some users report similar results with fluridil and pyrilutamide, while others find pyrilutamide less effective compared to prescription treatments.

      community Figuring out my own experimental protocol

      in Treatment  11 upvotes 3 years ago
      User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

      community 1 year Fin/2 months GHK-CU update

      in Update  128 upvotes 2 months ago
      The user has been using oral finasteride for over a year and recently added GHK-CU for two months, seeing progress but seeking further improvement, especially on the hairline. They discuss sourcing GHK-CU, its effects, and the importance of third-party testing, while considering additional treatments like dutasteride and hair transplants for better results.

      community New Hair Loss Cure: AMP-303 Is Back. It’s what PP405 should have been.

      in Research/Science  5 upvotes 4 months ago
      AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

      community DLQ01: A Better "Minoxidil" PGF2a synthetic analogue.

      in Research/Science  3 upvotes 1 year ago
      DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

      community Sapphire FUE vs Standard FUE: what we’ve actually seen in practice

      in Hair Transplants  168 upvotes 2 weeks ago
      Sapphire FUE uses sapphire-tipped blades for more precise incisions, but the surgeon's skill and overall procedure management are more crucial for success than the blade type. Both Sapphire and Standard FUE can yield similar results, with recovery influenced more by individual factors and aftercare than the blade used.

      community For those of you applying Pyrilutamide, what's your plan B?

      in Treatment  6 upvotes 2 years ago
      The user switched from Pyrilutamide to RU58841, changed their Minoxidil solution, and continued using low-dose Finasteride, derma rolling, and specific shampoo. They asked others about their plans after Pyrilutamide's disappointing results.

      community SCUBE3 Biannual Injections and Microneedling

      in Technology  12 upvotes 2 years ago
      The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

      community Recommended AHK-Cu peptide brand?

      in Treatment  1 upvotes 1 year ago
      AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

      community So I hacked the AAD 2026 live stream

      in Chat  42 upvotes 4 months ago
      The conversation discusses a live stream presentation on Pelage PP405 for hair regrowth, with skepticism about its effectiveness compared to minoxidil. Some users express doubt and suggest sticking to proven treatments like minoxidil, finasteride, and RU58841.

      community Application tip for topicals. 1ml TB Syringe & Opthalmic Cannula.

      in Product  66 upvotes 2 years ago
      The post and conversation discuss different methods of applying hair loss treatments directly to the scalp. The original poster suggests using a 1ml TB Syringe & Ophthalmic Cannula for precise application, while others share their own methods, including sprays, droppers, and simple syringes.

      community Binding affinity of pyrilutamide!

      in Update  168 upvotes 4 years ago
      Pyrilutamide, a nonsteroidal antiandrogen drug under development for the potential treatment of androgenic alopecia. The conversation discusses its binding affinity to the androgen receptor and the timeline for possible availability after trials are completed in the United States and China.

      community The Solution for Topical Solutions

      in Product  6 upvotes 9 months ago
      Using roll-on bottles for applying minoxidil and RU58841 improves application efficiency and reduces product waste. Topical treatments are used continuously, except on microneedling days.

      community PP405 2a study was a safety study. Some rational explaining.

      in Research/Science  22 upvotes 11 months ago
      The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.